Physician profile
Frances A Mccay
NPI 1194984559
$3,937.55
in general payments reported to CMS, 2019-2025
23 companies · $656 in 2025
The $656 reported for 2025 was more than what 88% of Critical Care Medicine (Nurse Practitioner) providers received nationally (typical 2025 total: $118).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $414 · 2022: $1,239 · 2023: $843 · 2024: $785 · 2025: $656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,284.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,362.35 | 2021-2024 | Leqvio |
| Amgen INC. | $724.19 | 2021-2025 | Repatha, Repatha |
| Heartflow, INC. | $262.27 | 2023-2025 | Ffrct |
| Boehringer Ingelheim Pharmaceuticals, INC. | $218.71 | 2021-2025 | Jardiance |
| Cvrx, INC. | $200.34 | 2022-2024 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $194.38 | 2021-2023 | Xarelto |
| Pfizer INC. | $180.76 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $143.15 | 2022-2025 | Verquvo, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $115.05 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $98.77 | 2021-2024 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $90.48 | 2021-2025 | Camzyos |
| Impulse Dynamics (USA) INC. | $61.81 | 2022-2023 | Optimizer |
| Esperion Therapeutics, INC. | $51.52 | 2021-2024 | Nexletol |
| Regeneron Healthcare Solutions, INC. | $47.82 | 2023-2025 | Evkeeza |
| Inspire Medical Systems, INC. | $31.90 | 2025 | Inspire |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $24.84 | 2022 | |
| Novo Nordisk INC | $22.99 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.39 | 2022-2025 | Lifevest |
| Daiichi Sankyo INC. | $20.73 | 2025 | Injectafer |
| Sanofi-Aventis U.S. LLC | $19.74 | 2023 | |
| Abbott Laboratories | $15.74 | 2024 | Cardiomems |
| Arbor Pharmaceuticals, INC. | $13.94 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $13.68 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frances Mccay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.